Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline.
Emrullah YilmazNofisat IsmailaJulie E BaumanRaetasha DabneyGregory GanRichard JordanMarnie KaufmanKedar S KirtaneSean Matthew McBrideMatthew O OldLisa RooperNabil F SabaSiddharth H ShethRathan M SubramaniamTrisha Michel Wise-DraperDeborah J WongLoren K MellPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
When possible, evidence-based recommendations were developed to address biomarker testing, first-line treatment regimens based on programmed death ligand-1 scores, immunotherapy in platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma, immunotherapy in nasopharyngeal carcinoma, and radiation therapy in combination with immunotherapy for treatment of local recurrence.Additional information is available at www.asco.org/head-neck-cancer-guidelines.